Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Merck & Co – known as MSD outside of the US and Canada – and Cyprumed have entered into a partnership aimed at developing ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

Last year Merck agreed a similar licensing deal, also worth $2 billion, for Chinese biotech Hansoh Pharma’s experimental oral obesity drug, while yesterday Denmark’s Novo Nordisk (NVO) bought the ...

The alliance gives the company “an important addition that expands and complements our cardio-metabolic pipeline,” said Dean Li, president of Merck Research Laboratories, in a statement.

Dean Li, president of Merck Research Laboratories, told the meeting that cardiovascular disease is a big opportunity as it remains an epidemic, killing 35 million people during the pandemic while ...

Li, president, Merck Research Laboratories, in a press release. “HRS-5346, an investigational oral small molecule inhibitor of Lp(a) formation, is an important addition that expands and complements ...

Merck Life Science South Africa, a leading science and technology company, is excited to announce its participation as a bronze sponsor at Analytica Lab Africa 2025. This major trade fair for ...

Merck complemented its 2010 acquisition of Millipore by acquiring Sigma-Aldrich for USD 17 billion in 2015, significantly expanding its Science and Lab Solutions portfolio and giving the company ...

Li, president, Merck Research Laboratories. “HRS-5346, an investigational oral small molecule inhibitor of Lp(a) formation, is an important addition that expands and complements our cardio ...